{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:44:49Z","timestamp":1787244289778,"version":"build-2736575974"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"name":"QREN"},{"DOI":"10.13039\/501100008530","name":"FEDER","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011929","name":"COMPETE","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011929","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.lfs.2018.07.010","type":"journal-article","created":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T06:51:04Z","timestamp":1530859864000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Platinum-induced muscle wasting in cancer chemotherapy: Mechanisms and potential targets for therapeutic intervention"],"prefix":"10.1016","volume":"208","author":[{"given":"Alexandra","family":"Moreira-Pais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2151-2449","authenticated-orcid":false,"given":"Rui","family":"Gil da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2018.07.010_bb0005","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study","volume":"3","author":"Fitzmaurice","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lfs.2018.07.010_bb0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lfs.2018.07.010_bb0015","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0163-7258(01)00132-2","article-title":"Differentiation therapy of human cancer: basic science and clinical applications","volume":"90","author":"Leszczyniecka","year":"2001","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2018.07.010_bb0020","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lfs.2018.07.010_bb0025","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1021\/acs.jmedchem.6b01351","article-title":"A drug of such damned nature.1 challenges and opportunities in translational platinum drug research","volume":"60","author":"Cheff","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2018.07.010_bb0030","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/jcsm.12023","article-title":"Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved","volume":"6","author":"Chen","year":"2015","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.lfs.2018.07.010_bb0035","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/en.2007-0828","article-title":"Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia","volume":"149","author":"Garcia","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.lfs.2018.07.010_bb0040","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.tem.2016.03.002","article-title":"Cytokine signaling in skeletal muscle wasting","volume":"27","author":"Zhou","year":"2016","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2018.07.010_bb0045","first-page":"1","article-title":"Supplementation of magnolol attenuates skeletal muscle atrophy in bladder cancer-bearing mice undergoing chemotherapy via suppression of FoxO3 activation and induction of IGF-1","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2018.07.010_bb0050","first-page":"8","article-title":"Role of NF-KB in loss of skeletal muscle mass in cancer cachexia and its therapeutic targets","volume":"1","author":"Srivastava","year":"2013","journal-title":"Am. J. Cancer Biol."},{"key":"10.1016\/j.lfs.2018.07.010_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphys.2016.00472","article-title":"Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways","volume":"7","author":"Barreto","year":"2016","journal-title":"Front. Physiol."},{"key":"10.1016\/j.lfs.2018.07.010_bb0060","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nrc3829","article-title":"Cancer cachexia: understanding the molecular basis","volume":"14","author":"Argil\u00e9s","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lfs.2018.07.010_bb0065","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nrd4467","article-title":"Muscle wasting in disease: molecular mechanisms and promising therapies","volume":"14","author":"Cohen","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2018.07.010_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106489","article-title":"Muscle atrophy in response to cytotoxic chemotherapy is dependent on intact glucocorticoid signaling in skeletal muscle","volume":"9","author":"Braun","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2018.07.010_bb0075","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.critrevonc.2012.03.002","article-title":"Cancer chemotherapy: a critical analysis of its 60\u202fyears of history","volume":"84","author":"Galmarini","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.lfs.2018.07.010_bb0080","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2141.2006.06119.x","article-title":"A tribute to Sidney Farber \u2013 the father of modern chemotherapy","volume":"134","author":"Miller","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lfs.2018.07.010_bb0085","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.chembiol.2013.04.007","article-title":"DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology","volume":"20","author":"Cheung-Ong","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.lfs.2018.07.010_bb0090","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin)","volume":"238","author":"Farber","year":"1948","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2018.07.010_bb0095","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/1440-1681.12581","article-title":"Molecular mechanisms for tumour resistance to chemotherapy","volume":"43","author":"Pan","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.lfs.2018.07.010_bb0100","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/cancers3011351","article-title":"Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects","volume":"3","author":"Florea","year":"2011","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lfs.2018.07.010_bb0105","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.taap.2014.05.001","article-title":"Mechanisms of cisplatin-induced muscle atrophy","volume":"278","author":"Sakai","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.lfs.2018.07.010_bb0110","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","article-title":"Cisplatin: mode of cytotoxic action and molecular basis of resistance","volume":"22","author":"Siddik","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.lfs.2018.07.010_bb0115","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.lfs.2010.06.014","article-title":"Epigallocatechin-3-gallate activates Nrf2\/HO-1 signaling pathway in cisplatin-induced nephrotoxicity in rats","volume":"87","author":"Sahin","year":"2010","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2018.07.010_bb0120","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1124\/jpet.108.139162","article-title":"Regulation and pathological role of p53 in cisplatin nephrotoxicity","volume":"327","author":"Jiang","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.lfs.2018.07.010_bb0125","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd1691","article-title":"Cellular processing of platinum anticancer drugs","volume":"4","author":"Wang","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2018.07.010_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0027-5107(01)00142-7","article-title":"Recognition of cisplatin adducts by cellular proteins","volume":"478","author":"Kartalou","year":"2001","journal-title":"Mutat. Res."},{"key":"10.1016\/j.lfs.2018.07.010_bb0135","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3892\/etm.2011.247","article-title":"New perspective for nutritional support of cancer patients: enteral\/parenteral nutrition","volume":"2","author":"Akbulut","year":"2011","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.lfs.2018.07.010_bb0140","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/sj.bjc.6601887","article-title":"High levels of untreated distress and fatigue in cancer patients","volume":"90","author":"Carlson","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lfs.2018.07.010_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022538","article-title":"STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia","volume":"6","author":"Bonetto","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2018.07.010_bb0150","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1096\/fj.01-0866com","article-title":"Activation of an alternative NF-\u03baB pathway in skeletal muscle during disuse atrophy","volume":"16","author":"Hunter","year":"2002","journal-title":"FASEB J."},{"key":"10.1016\/j.lfs.2018.07.010_bb0155","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3945\/ajcn.113.058388","article-title":"Nuclear transcription factor \u03baB activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia","volume":"98","author":"Op den Kamp","year":"2013","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.lfs.2018.07.010_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/805172","article-title":"Role of inflammation in muscle homeostasis and myogenesis","volume":"2015","author":"Costamagna","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.lfs.2018.07.010_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109030","article-title":"Voluntary exercise prevents cisplatin-induced muscle wasting during chemotherapy in mice","volume":"9","author":"Hojman","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2018.07.010_bb0170","doi-asserted-by":"crossref","first-page":"43442","DOI":"10.18632\/oncotarget.9779","article-title":"Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1\/2 and p38 MAPKs","volume":"7","author":"Barreto","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2018.07.010_bb0175","first-page":"1","article-title":"Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90","volume":"8","author":"Zhang","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2018.07.010_bb0180","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/jcsm.12185","article-title":"Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia","volume":"8","author":"Conte","year":"2017","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.lfs.2018.07.010_bb0185","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1042\/bse0410173","article-title":"The ubiquitin-proteasome system and skeletal muscle wasting","volume":"41","author":"Attaix","year":"2005","journal-title":"Essays Biochem."},{"key":"10.1016\/j.lfs.2018.07.010_bb0190","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev.nutr.26.061505.111151","article-title":"Cancer-associated cachexia and underlying biological mechanisms","volume":"26","author":"Baracos","year":"2006","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.lfs.2018.07.010_bb0195","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1681\/ASN.2006010083","article-title":"Protein degradation by the ubiquitin-proteasome pathway in normal and disease states","volume":"17","author":"Lecker","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2018.07.010_bb0200","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1126\/science.1065874","article-title":"Identification of ubiquitin ligases required for skeletal muscle atrophy","volume":"294","author":"Bodine","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.lfs.2018.07.010_bb0205","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/jcsm.12043","article-title":"Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training","volume":"6","author":"Bowen","year":"2015","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.lfs.2018.07.010_bb0210","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.tem.2013.09.004","article-title":"Skeletal muscle autophagy: a new metabolic regulator","volume":"24","author":"Neel","year":"2013","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2018.07.010_bb0215","doi-asserted-by":"crossref","DOI":"10.1038\/srep26991","article-title":"Aerobic exercise and pharmacological treatments counteract cachexia by modulating autophagy in colon cancer","volume":"6","author":"Pigna","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2018.07.010_bb0220","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1242\/dmm.010389","article-title":"Cellular and molecular mechanisms of muscle atrophy","volume":"6","author":"Bonaldo","year":"2013","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.lfs.2018.07.010_bb0225","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/MCO.0000000000000048","article-title":"Coming back: autophagy in cachexia","volume":"17","author":"Penna","year":"2014","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"10.1016\/j.lfs.2018.07.010_bb0230","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.taap.2010.11.003","article-title":"Cisplatin triggers atrophy of skeletal C2C12 myotubes via impairment of Akt signalling pathway and subsequent increment activity of proteasome and autophagy systems","volume":"250","author":"Fanzani","year":"2011","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.lfs.2018.07.010_bb0235","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling, and metabolic pathways","volume":"16","author":"Fearon","year":"2012","journal-title":"Cell Metab."},{"key":"10.1016\/j.lfs.2018.07.010_bb0240","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1158\/1078-0432.CCR-16-0495","article-title":"Molecular pathways: cachexia signaling - a targeted approach to cancer treatment","volume":"22","author":"Miyamoto","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2018.07.010_bb0245","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/10409238.2013.857291","article-title":"Signaling pathways controlling skeletal muscle mass","volume":"49","author":"Egerman","year":"2014","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.lfs.2018.07.010_bb0250","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.febslet.2010.01.017","article-title":"mTOR regulation of autophagy","volume":"584","author":"Jung","year":"2010","journal-title":"FEBS Lett."},{"key":"10.1016\/j.lfs.2018.07.010_bb0255","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/SPC.0b013e32834bddf9","article-title":"Targeting the myostatin signaling pathway to treat muscle wasting diseases","volume":"5","author":"Han","year":"2011","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"10.1016\/j.lfs.2018.07.010_bb0260","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10838-5","article-title":"The histone deacetylase SIRT6 blocks myostatin expression and development of muscle atrophy","volume":"7","author":"Samant","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2018.07.010_bb0265","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13539-011-0035-5","article-title":"The role of myostatin in muscle wasting: an overview","volume":"2","author":"Elkina","year":"2011","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.lfs.2018.07.010_bb0270","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1249\/JES.0000000000000041","article-title":"TGF-\u03b2 superfamily signaling in muscle and tendon adaptation to resistance exercise","volume":"43","author":"Gumucio","year":"2015","journal-title":"Exerc. Sport Sci. Rev."},{"key":"10.1016\/j.lfs.2018.07.010_bb0275","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1530\/JOE-15-0170","article-title":"Molecular and neuroendocrine mechanisms of cancer cachexia","volume":"226","author":"Mendes","year":"2015","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.lfs.2018.07.010_bb0280","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1126\/science.289.5488.2363","article-title":"NF-\u03baB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia","volume":"289","author":"Guttridge","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.lfs.2018.07.010_bb0285","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s00535-013-0787-0","article-title":"Cancer cachexia\u2014pathophysiology and management","volume":"48","author":"Suzuki","year":"2013","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.lfs.2018.07.010_bb0290","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature04870","article-title":"Nuclear factor-\u03baB in cancer development and progression","volume":"441","author":"Karin","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2018.07.010_bb0295","first-page":"139","article-title":"Chemotherapy-induced muscle wasting: association with NF-kB and cancer cachexia","volume":"18","author":"Damrauer","year":"2008","journal-title":"Basic Appl. Myol."},{"key":"10.1016\/j.lfs.2018.07.010_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1010428317706917","article-title":"Sporamin induces apoptosis and inhibits NF-\u03baB activation in human pancreatic cancer cells","volume":"39","author":"Qian","year":"2017","journal-title":"Tumor Biol."},{"key":"10.1016\/j.lfs.2018.07.010_bb0305","doi-asserted-by":"crossref","first-page":"11432","DOI":"10.1158\/0008-5472.CAN-06-1867","article-title":"p50 nuclear factor-\u03baB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance","volume":"66","author":"Saccani","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2018.07.010_bb0310","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2004.09.027","article-title":"IKK\u03b2\/NF-\u03baB activation causes severe muscle wasting in mice","volume":"119","author":"Cai","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2018.07.010_bb0315","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00109-008-0373-8","article-title":"Nuclear factor-kappa B signaling in skeletal muscle atrophy","volume":"86","author":"Li","year":"2008","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.lfs.2018.07.010_bb0320","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2217\/fon.15.195","article-title":"Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches","volume":"11","author":"Madeddu","year":"2015","journal-title":"Future Oncol."},{"key":"10.1016\/j.lfs.2018.07.010_bb0325","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/1471-2091-8-S1-S7","article-title":"Roles and potential therapeutic targets of the ubiquitin proteasome system in muscle wasting","volume":"8","author":"Nury","year":"2007","journal-title":"BMC Biochem."},{"key":"10.1016\/j.lfs.2018.07.010_bb0330","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1159\/000048556","article-title":"Anti-cachectic effect of clarithromycin for patients with unresectable non-small cell lung cancer","volume":"47","author":"Sakamoto","year":"2001","journal-title":"Chemotherapy"},{"key":"10.1016\/j.lfs.2018.07.010_bb0335","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/gut.2004.047563","article-title":"Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial","volume":"54","author":"Gordon","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.lfs.2018.07.010_bb0340","doi-asserted-by":"crossref","first-page":"22382","DOI":"10.1074\/jbc.M100938200","article-title":"Inhibition of NF-\u03baB activity by thalidomide through suppression of I\u03baB kinase activity","volume":"276","author":"Keifer","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2018.07.010_bb0345","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00109-009-0547-z","article-title":"Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia","volume":"88","author":"Mantovani","year":"2010","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.lfs.2018.07.010_bb0350","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival","volume":"142","author":"Zhou","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2018.07.010_bb0355","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1158\/1535-7163.MCT-14-0681","article-title":"Myostatin neutralization results in preservation of muscle mass and strength in preclinical models of tumor-induced muscle wasting","volume":"14","author":"Smith","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lfs.2018.07.010_bb0360","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/sj.bjc.6602165","article-title":"Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF- \u03baB activation","volume":"91","author":"Wyke","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lfs.2018.07.010_bb0365","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.lfs.2016.10.031","article-title":"HPV16 induces a wasting syndrome in transgenic mice: amelioration by dietary polyphenols via NF-\u03baB inhibition","volume":"169","author":"Gil da Costa","year":"2017","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2018.07.010_bb0370","doi-asserted-by":"crossref","first-page":"022","DOI":"10.4172\/1948-5956.1000052","article-title":"Selective inhibition of NF-kappa-B with NBD peptide reduces tumor-induced wasting in a murine model of cancer cachexia in vivo","volume":"3","author":"Wysong","year":"2011","journal-title":"J. Cancer Sci. Ther."},{"key":"10.1016\/j.lfs.2018.07.010_bb0375","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/SPC.0000000000000012","article-title":"Clinical development of ghrelin axis-derived molecules for cancer cachexia treatment","volume":"7","author":"Ali","year":"2013","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"10.1016\/j.lfs.2018.07.010_bb0380","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1210\/jc.2004-1788","article-title":"Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia","volume":"90","author":"Garcia","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2018.07.010_bb0385","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/1758834017698643","article-title":"Cancer-induced muscle wasting: latest findings in prevention and treatment","volume":"9","author":"Aversa","year":"2017","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.lfs.2018.07.010_bb0390","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1207\/S15327914NC3602_6","article-title":"Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer","volume":"36","author":"Wigmore","year":"2000","journal-title":"Nutr. Cancer"},{"key":"10.1016\/j.lfs.2018.07.010_bb0395","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/0148607102026005291","article-title":"Eicosapentaenoic acid supplementation reduces tumor volume and attenuates cachexia in a rat model of progressive non-metastasizing malignancy","volume":"26","author":"Jho","year":"2002","journal-title":"J. Parenter. Enter. Nutr."},{"key":"10.1016\/j.lfs.2018.07.010_bb0400","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1042\/BJ20070651","article-title":"Effect of branched-chain amino acids on muscle atrophy in cancer cachexia","volume":"407","author":"Eley","year":"2007","journal-title":"Biochem. J."},{"key":"10.1016\/j.lfs.2018.07.010_bb0405","doi-asserted-by":"crossref","DOI":"10.1007\/s00424-017-2045-4","article-title":"Effect of acute treadmill exercise on cisplatin-induced muscle atrophy in the mouse","author":"Sakai","year":"2017","journal-title":"Pflugers Arch. - Eur. J. Physiol."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320518303874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320518303874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T05:30:13Z","timestamp":1742362213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320518303874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":81,"alternative-id":["S0024320518303874"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2018.07.010","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Platinum-induced muscle wasting in cancer chemotherapy: Mechanisms and potential targets for therapeutic intervention","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2018.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}